Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adult-onset Still's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Adult-onset Still's disease. Displaying page 1 of 1.
    EudraCT Number: 2014-002500-24 Sponsor Protocol Number: AOSD.2014.001 Start Date*: 2015-02-19
    Sponsor Name:AB2 Bio Ltd.
    Full Title: Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients ...
    Medical condition: Adult -onset Still’s Disease (AoSD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10064056 Still's disease adult onset PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001027-20 Sponsor Protocol Number: CACZ885GDE01T Start Date*: 2012-04-03
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.
    Medical condition: adult onset Still's disease (AOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042061 Still's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001779-22 Sponsor Protocol Number: 04.2017 Start Date*: 2017-07-10
    Sponsor Name:Aarhus University Hospital, Department of Endocrinology
    Full Title: The Effect of Empagliflozin on Cardiac and Kidney Metabolism in Persons with Type 2 Diabetes
    Medical condition: Diabetes, type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003173-24 Sponsor Protocol Number: AOSD Study 05 Start Date*: 2005-12-22
    Sponsor Name:Helsinki University Central Hospital
    Full Title: An open, randomized study treating refractory adult-onset Still´s disease (AOSD) with interleukin-1 receptor antagonist anakinra (KineretR), compared to an established, single anti-rheumatic drug t...
    Medical condition: Refractory adult onset Still´s disease (AOSD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001454-33 Sponsor Protocol Number: DEXBASU Start Date*: 2017-08-07
    Sponsor Name:Dr. Albert Lecube Torello
    Full Title: A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surg...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002457-24 Sponsor Protocol Number: 1218.17 Start Date*: 2008-01-24
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient ...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017524-36 Sponsor Protocol Number: DUT-MD-403 Start Date*: 2010-05-18
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A Phase III, Multicenter, Double-blind, Active-Controlled, 52-Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background ...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012652-24 Sponsor Protocol Number: SYR-322MET_302 Start Date*: 2010-03-23
    Sponsor Name:Takeda Global Research and Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 D...
    Medical condition: Type II diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-005383-51 Sponsor Protocol Number: H7U-MC-IDAZ Start Date*: 2007-01-12
    Sponsor Name:Lilly S.A.
    Full Title: A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 ...
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017266-23 Sponsor Protocol Number: DUT-MD-308 Start Date*: 2010-04-21
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Safety Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus Treated With Dutogliptin
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000881-23 Sponsor Protocol Number: MYL-GAI-3002 Start Date*: 2014-10-28
    Sponsor Name:MYLAN GmbH
    Full Title: AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001102-17 Sponsor Protocol Number: CV181363 Start Date*: 2015-03-27
    Sponsor Name:AstraZeneca AB
    Full Title: A 26-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 26-week Long -term Extension Period to Evaluate the Efficacy and Safe...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004369-34 Sponsor Protocol Number: UMC-NMZ-SMA2011 Start Date*: 2015-04-22
    Sponsor Name:Universtiy Medical Center Utrecht
    Full Title: SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients ...
    Medical condition: Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10068209 Spinal muscular atrophy adult onset LLT
    17.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002013-21 Sponsor Protocol Number: THR-1442-C-480 Start Date*: 2016-09-01
    Sponsor Name:Theracos Sub, LLC
    Full Title: A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin versus Glimepiride in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Contr...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001577-24 Sponsor Protocol Number: NI-0501-14 Start Date*: 2021-12-15
    Sponsor Name:Swedish Orphan Biovitrum AG (Sobi AG)
    Full Title: A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage ac...
    Medical condition: Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD). MAS in the context of pediatric and adult Systemic lup...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10071583 Haemophagocytic lymphohistiocytosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Trial now transitioned) PL (Completed) DE (Completed) CZ (Trial now transitioned) BE (Completed) SE (Completed) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016604-23 Sponsor Protocol Number: CACZ885I2207 Start Date*: 2010-05-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...
    Medical condition: Impaired Glucose Tolerance and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003721-18 Sponsor Protocol Number: CV181365 Start Date*: 2015-09-14
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long -term Extension Period to Evaluate the Efficacy and Saf...
    Medical condition: Inadequately controlled Diabetes Mellitus Type 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) SE (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004223-23 Sponsor Protocol Number: NI-0501-06 Start Date*: 2017-04-14
    Sponsor Name:Novimmune SA
    Full Title: A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo...
    Medical condition: Macrophage activation syndrome / Secondary hemophagocytic lymphohistiocytosis (MAS/sHLH) in patients with Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10053867 Macrophage activation syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002324-32 Sponsor Protocol Number: I4V-MC-JADZ Start Date*: 2013-02-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who H...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) GB (Completed) PT (Completed) AT (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:15:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA